Hamilton Thorne to Participate in 6th Annual Lake Street Capital Markets Best Ideas Growth… | New

BEVERLY, Mass. and TORONTO, Sept. 02, 2022 (GLOBE NEWSWIRE) — Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of precision instruments, consumables, software and services for the assisted reproductive technologies (ART), research and cell biology markets, announced today today that the company will be participating in the 6th Annual Lake Steet Capital Markets Best Ideas Growth Conference to be held at the Yale Club in New York, NY on September 14, 2022.

David Wolf, President and CEO, and Francesco Fragasso, Chief Financial Officer of Hamilton Thorne Ltd., will be available for one-on-one meetings with institutional analysts and investors during the conference. To schedule a meeting with management, please contact your conference representative or email [email protected]

Stock incentive plan

The Company also announced that on September 1, 2022, it granted a total of 200,000 common stock options and 28,897 restricted stock units (“RSUs”) to the Company’s Chief Financial Officer pursuant to the The Company’s 2019 Long-Term Equity Incentive Plan (the “Plan”). The options are exercisable at CA$1.50 per share and expire ten years from the date of grant. Each vested RSU is entitled to its option grants vest over four years and RSUs vest over three years.

About Hamilton Thorne Ltd. ( www.hamiltonthorne.ltd )

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce costs, increase productivity, improve outcomes and enable breakthroughs in assisted reproductive technology (ART) markets ), research and cell biology. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base includes fertility clinics, academic research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research institutions.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information please contact:

Copyright 2022 GlobeNewswire, Inc.